

Article Corrected

Mueck W, Lensing AWA, Agnelli G, Decousus H, Prandoni P, Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011; 50 (10): 675-86

Corrections Made

The authors have alerted us to errors in a figure, which have now been corrected as follows:

Page 681, figure 3: The graph in panel (a) has been redrawn to correct errors in the data series for a typical patient aged 60 years, weighing 80 kg, CL_{CR} 90 mL/min, and in the order of the data series in relation to the key for a patient aged 90 years, weighing ~45 kg, and a patient with CL_{CR} ~35 mL/min. The graph in panel (b) has been redrawn to correct errors in the data series for a typical patient aged 60 years, weighing 80 kg, CL_{CR} 90 mL/min.

A corrected version of the figure is shown below:




Fig. 3. Predicted plasma rivaroxaban concentration-time profiles for extremes in age, renal function and body weight for patients receiving (a) rivaroxaban 20 mg once daily or (b) rivaroxaban 10 mg twice daily. The simulated patients had typical mean characteristics (age 60 years, body weight 80 kg, creatinine clearance [CL_{CR}] 90 mL/min) unless specified otherwise.

Note

All online versions of this article have been updated to reflect these corrections.